Intravesical botulinum toxin type A in chronic interstitial cystitis: Results of a pilot study

Ramsay, AK; Small, D. R.; Conn, I G

doi:10.1016/s1479-666x(07)80084-9

Cited by 23 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pilot studies reporting the efficacy of BoNT‐A for treating IC/PBS since 2004 have revealed controversial results 12,107,108 . However, most recent studies support the effects of BoNT‐A in patients with chronic IC/PBS 108–116 . All nine articles mentioned in Table 3 reporting the use of BoNT‐A for IC/PBS utilized onabotulinumtoxinA.…”

Section: Therapeutic Effects Of Botox On Ic/pbsmentioning

confidence: 99%

See 1 more Smart Citation

Botulinum toxin injection for lower urinary tract dysfunction

Kuo

2012

Int J of Urology

View full text Add to dashboard Cite

Abbreviations & Acronyms 5ARI = 5-alpha-reductase inhibitor Ach = acetylcholine AD = autonomic dysreflexia ATP = adenosine triphosphate BCG = bacillus Calmette-Guérin BoNT = botulinum toxin BoNT-A = botulinum toxin type A BOO = bladder outlet obstruction BPH = benign prostatic hyperplasia CGRP = calcitonin gene-related peptide Abstract: Botulinum toxin has been recently accepted as a novel treatment for lower urinary tract dysfunctions refractory to conventional treatment. Review of the clinical trials in recent years, botulinum toxin type A has been widely used in the urethra or urinary bladder to treat voiding dysfunction due to detrusor sphincter dyssynergia, incontinence due to neurogenic or idiopathic detrusor overactivity, sensory disorders such as bladder hypersensitivity, overactive bladder, and interstitial cystitis/painful bladder syndrome. Intravesical botulinum toxin type A injection is effective in treatment of urinary incontinence due to detrusor overactivity in men and women, as well as in children. Currently botulinum toxin type A has also been applied to treat lower urinary tract symptoms due to benign prostatic hyperplasia in patients not suitable for surgery. This article reviewed the recent advances of botulinum toxin type A on lower urinary tract dysfunction.

show abstract

Section: Therapeutic Effects Of Botox On Ic/pbsmentioning

confidence: 99%

“…12,107,108 However, most recent studies support the effects of BoNT-A in patients with chronic IC/PBS. [108][109][110][111][112][113][114][115][116] All nine articles mentioned in Table 3 reporting the use of BoNT-A for IC/PBS utilized onabotulinumtoxinA. Of these, one study was level 1 and two were level 2.…”

Section: Efficacy Of Bont-a On Ic/pbsmentioning

confidence: 99%

Botulinum toxin injection for lower urinary tract dysfunction

Kuo

2012

Int J of Urology

View full text Add to dashboard Cite

show abstract

“…These findings suggest a benefit in treatment of neurogenic inflammation. Though results from available clinical trials are inconclusive, experimental data support the use of BTX-A in patients with painful bladder syndrome and interstitial cystitis [75,76]. Lui and Kuo [77] reported that BTX-A significantly reduced nerve growth factor mRNA expression, obtained from interstitial cystitis patient mucosal biopsies, and this correlated with a reduction in the associated bladder pain.…”

Section: Botulinum Toxinmentioning

confidence: 99%

New insights into the pharmacology of the bladder

Hanna-Mitchell¹,

Birder²

2008

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review Pharmacotherapy of a number of bladder disorders has traditionally focused on targeting the ‘sensory’ component or bladder nerves and the smooth muscle. This review aims to provide an insight into recent (experimental and clinical) developments in mechanisms of existing therapies as well as novel targets. Recent findings Traditionally, sensory signaling in the urinary bladder has been attributed to activation of bladder afferents, but new findings have pointed to the urothelium and interstitial cells as key participants in the transduction of sensory events. Recent advances provide strong support for the development of subtype selective receptor agonists/antagonists, the modulation of signal transduction cascades and new and expanded uses for various neurotoxins. Summary The development of therapeutic options for the treatment of a number of bladder disorders is complicated, and most treatments are associated with an increased incidence of side effects or lack of specificity. Recent studies suggest that selective targeting of receptors/ion channels or a disease-specific (i.e. phosphorylated) form of the receptor may represent a viable therapeutic target. Though the mechanisms regulating ion channel expression under pathological conditions are not fully known, an increased understanding of these pathways has important implications for drug development.

show abstract

“…Smith et al [24] in 2004 evaluated the use of BoNT-A in interstitial cystitis in 13 patients and found a significant overall reduction in pain scores, 69% of patients reporting subjective improvement. Ramsay et al [27] injected throughout the bladder 200 IU (n ¼ 9) and 300 IU (n ¼ 2) of OnabotulinumtoxinA in patients with refractory interstitial cystitis and found statistically significant improvements in Bristol Female Lower Urinary Tract Symptom (BFLUTS) questionnaire scores from 6 weeks and in the King's Health questionnaire (KHQ) at 10 weeks. Kuo [25], in his first study assessing either bladder injections of 100 IU or bladder and trigonal injections totalling 200 IU OnabotulinumtoxinA, showed no difference between the two injection techniques and disappointingly only a 20% improvement.…”

Section: Key Pointsmentioning

confidence: 99%